The University of Oxford in the UK released on October 11. The results of the first phase of clinical tests showed that the nasal spray novel coronavirus pneumonia (COVID-19) vaccine jointly developed with the pharmaceutical company AstraZeneca (AstraZeneca) provided less protection than expected.
Participants in this clinical test include 30 people who have not received the new crown vaccine , and 12 people who have received two doses of the new crown vaccine. Oxford University html issued a statement on the 211th, saying that the first phase of clinical tests showed that only a few participants had antibody responses in the respiratory mucosa, and the immune response recorded in the blood was weaker than the immune response caused by vaccination.
During the clinical testing period, the research team did not receive any reports of serious adverse reactions or safety concerns among participants.
Sandy Douglas, a member of the Jenner Institute at Oxford and lead investigator for clinical testing, said the nasal spray vaccine did not perform as well in the study as they expected. Douglas said they believe that delivering the vaccine to the nose and lungs is still a desirable approach, but the study shows that the team may face challenges if they want to make nasal spray vaccines a reliable option.
